Molecure Receives Favorable IDMC Recommendation to Continue KITE Clinical Trial Without Protocol Modification (OATD-01 Development Program)

WARSAW, Poland, August 4, 2026 (GLOBE NEWSWIRE) -- Molecure S.A. (WSE: MOC), a clinical-stage biotechnology company, has received a favorable recommendation from the Independent Data Monitoring Committee (IDMC) to continue, without protocol modification, the Phase II KITE clinical trial. This trial evaluates the efficacy and safety of OATD-01, a first-in-class CHIT1 inhibitor, in patients with active pulmonary sarcoidosis.